{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T08:00:53Z","timestamp":1789891253729,"version":"4.0.1"},"reference-count":58,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The persisting effects questionnaire (PEQ) is a measure of self-reported positive and negative effects from psychedelic and other experiences. While this measure has been used in many studies on psychedelic substances, the scale has not been formally validated. The PEQ consists of over 140 items as well as several separate single items, causing high participant burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>Conduct statistical and qualitative validation procedures for the PEQ and generate a validated short form version (PEQ-SF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Validation procedures included (1) conducting exploratory factor analysis for dimensionality reduction, (2) correlations to establish convergent and divergent validity, (3) confirmatory factor analysis in a separate sample, (4) qualitative response process evaluation to ensure items are comprehensible, and (5) comparisons between the original PEQ and the short form in two psychedelic administration studies, one clinical, and one in healthy normals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We found that the factor structure of the original PEQ was not quantitatively supported; factor analysis revealed a two-factor structure consisting of an overall positive and an overall negative factor. This two-factor structure was maintained in a short form version of the scale, consisting of 14 items with one positive valence and one negative valence factor and three single items from the original PEQ related to well-being and meaning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>We found that the original PEQ did not have adequate validity and created a short form with strong psychometric properties that behaves similarly in drug administration studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811261473405","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:28:28Z","timestamp":1789716508000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Validating and creating a short-form of the persisting effects questionnaire: A measure of positive and negative outcomes from psychedelic experiences"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2810-6045","authenticated-orcid":false,"given":"Rebecca","family":"Ehrenkranz","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Center for Psychedelic and Consciousness Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan D.","family":"Sepeda","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Center for Psychedelic and Consciousness Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA"},{"name":"Center for Psychedelic Drug Research and Education, The Ohio State University, Columbus, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5631-4346","authenticated-orcid":false,"given":"Sean P.","family":"Goldy","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Center for Psychedelic and Consciousness Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2989-2981","authenticated-orcid":false,"given":"Brandon M.","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Center for Psychedelic and Consciousness Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1762-0217","authenticated-orcid":false,"given":"Praachi","family":"Tiwari","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Center for Psychedelic and Consciousness Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arozo","family":"Azimi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Center for Psychedelic and Consciousness Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Yaden","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Center for Psychedelic and Consciousness Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"crossref","unstructured":"Adams DR Allen H Nicol GE et al. (2024) Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science. Translational Behavioral Medicine 14(12): 744\u2013752. https:\/\/doi.org\/10.1093\/TBM\/IBAE053","DOI":"10.1093\/tbm\/ibae053"},{"key":"e_1_3_2_3_1","doi-asserted-by":"crossref","unstructured":"Armstrong SB Davis AK (2024) Psychedelic research at a crossroads. Science (New York N.Y.) 385(6715): 1255. https:\/\/doi.org\/10.1126\/SCIENCE.ADT1024","DOI":"10.1126\/science.adt1024"},{"key":"e_1_3_2_4_1","doi-asserted-by":"crossref","unstructured":"Barnett BS Vest MF Delatte MS et al. (2025) Practical considerations in the establishment of psychedelic research programs. Psychopharmacology 242(1): 27\u201343. https:\/\/doi.org\/10.1007\/S00213-024-06722-6","DOI":"10.1007\/s00213-024-06722-6"},{"key":"e_1_3_2_5_1","doi-asserted-by":"crossref","unstructured":"Barrett FS Bradstreet MP Leoutsakos JMS et al. (2016) The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. Journal of Psychopharmacology (Oxford England) 30(12): 1279. https:\/\/doi.org\/10.1177\/0269881116678781","DOI":"10.1177\/0269881116678781"},{"key":"e_1_3_2_6_1","doi-asserted-by":"crossref","unstructured":"Barrett FS Doss MK Sepeda ND et al. (2020) Emotions and brain function are altered up to one month after a single high dose of psilocybin. Scientific Reports 10(1): 1\u201314. https:\/\/doi.org\/10.1038\/s41598-020-59282-y","DOI":"10.1038\/s41598-020-59282-y"},{"key":"e_1_3_2_7_1","doi-asserted-by":"crossref","unstructured":"Barrett FS Johnson MW Griffiths RR (2015) Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology 29(11): 1182\u20131190. https:\/\/doi.org\/10.1177\/0269881115609019","DOI":"10.1177\/0269881115609019"},{"key":"e_1_3_2_8_1","doi-asserted-by":"crossref","unstructured":"Bogenschutz MP Ross S Bhatt S et al. (2022) Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry 79(10): 953\u2013962. https:\/\/doi.org\/10.1001\/JAMAPSYCHIATRY.2022.2096","DOI":"10.1001\/jamapsychiatry.2022.2096"},{"key":"e_1_3_2_9_1","doi-asserted-by":"crossref","unstructured":"Braghetta CC Gorenstein C Wang YP et al. (2021) Development of an instrument to assess spirituality: Reliability and validation of the Attitudes Related to Spirituality Scale (ARES). Frontiers in Psychology 12: 764132. https:\/\/doi.org\/10.3389\/FPSYG.2021.764132","DOI":"10.3389\/fpsyg.2021.764132"},{"key":"e_1_3_2_10_1","doi-asserted-by":"crossref","unstructured":"Bremler R Katati N Shergill P et al. (2023) Case analysis of long-term negative psychological responses to psychedelics. Scientific Reports 13(1): 1\u201315. https:\/\/doi.org\/10.1038\/s41598-023-41145-x","DOI":"10.1038\/s41598-023-41145-x"},{"key":"e_1_3_2_11_1","doi-asserted-by":"crossref","unstructured":"Brown RT Nicholas CR Cozzi NV et al. (2017) Pharmacokinetics of escalating doses of oral psilocybin in healthy adults. Clinical Pharmacokinetics 56(12): 1543\u20131554. https:\/\/doi.org\/10.1007\/S40262-017-0540-6","DOI":"10.1007\/s40262-017-0540-6"},{"key":"e_1_3_2_12_1","doi-asserted-by":"crossref","unstructured":"Clifton JDW Baker JD Park CL et al. (2021) Primals Inventory. PsycTESTS Dataset. https:\/\/doi.org\/10.1037\/T79109-000","DOI":"10.1037\/t79109-000"},{"key":"e_1_3_2_13_1","doi-asserted-by":"crossref","unstructured":"Dittrich A (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31(SUPPL. 2): 80\u201384. https:\/\/doi.org\/10.1055\/S-2007-979351","DOI":"10.1055\/s-2007-979351"},{"issue":"1","key":"e_1_3_2_14_1","first-page":"1","article-title":"Pahnke\u2019s \u2018Good Friday Experiment\u2019: A long-term follow-up and methodological critique","volume":"23","author":"Doblin R","year":"1991","unstructured":"Doblin R (1991) Pahnke\u2019s \u2018Good Friday Experiment\u2019: A long-term follow-up and methodological critique. Journal of Transpersonal Psychology 23(1): 1\u201328.","journal-title":"Journal of Transpersonal Psychology"},{"key":"e_1_3_2_15_1","doi-asserted-by":"crossref","unstructured":"Ehrenkranz R Agrawal M Nayak SM et al. (2024) Adverse events should not be surprising in psychedelic research. Psychedelic Medicine 3(1): 59\u201362. https:\/\/doi.org\/10.1089\/PSYMED.2024.0006","DOI":"10.1089\/psymed.2024.0006"},{"key":"e_1_3_2_16_1","doi-asserted-by":"crossref","unstructured":"Evens R Schmidt ME Maji\u0107 T et al. (2023) The psychedelic afterglow phenomenon: A systematic review of subacute effects of classic serotonergic psychedelics. Therapeutic Advances in Psychopharmacology 13: 20451253231172254. https:\/\/doi.org\/10.1177\/20451253231172254","DOI":"10.1177\/20451253231172254"},{"key":"e_1_3_2_17_1","doi-asserted-by":"crossref","unstructured":"Forstmann M Yudkin DA Prosser AMB et al. (2020) Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings. Proceedings of the National Academy of Sciences of the United States of America 117(5): 2338\u20132346. https:\/\/doi.org\/10.1073\/PNAS.1918477117","DOI":"10.1073\/pnas.1918477117"},{"key":"e_1_3_2_18_1","doi-asserted-by":"crossref","unstructured":"Goldy SP Hendricks PS Keltner D et al. (2024) Considering distinct positive emotions in psychedelic science. International Review of Psychiatry (Abingdon England) 36(8): 908\u2013919. https:\/\/doi.org\/10.1080\/09540261.2024.2394221","DOI":"10.1080\/09540261.2024.2394221"},{"key":"e_1_3_2_19_1","doi-asserted-by":"crossref","unstructured":"Goodwin GM Aaronson ST Alvarez O et al. (2023) Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity anxiety function and quality of life. Journal of Affective Disorders 327: 120\u2013127. https:\/\/doi.org\/10.1016\/J.JAD.2023.01.108","DOI":"10.1016\/j.jad.2023.01.108"},{"key":"e_1_3_2_20_1","doi-asserted-by":"crossref","unstructured":"Griffiths RR Johnson MW Carducci MA et al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology (Oxford England) 30(12): 1181\u20131197. https:\/\/doi.org\/10.1177\/0269881116675513","DOI":"10.1177\/0269881116675513"},{"key":"e_1_3_2_21_1","doi-asserted-by":"crossref","unstructured":"Griffiths RR Johnson MW Richards WA et al. (2018) Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Journal of Psychopharmacology (Oxford England) 32(1): 49\u201369. https:\/\/doi.org\/10.1177\/0269881117731279","DOI":"10.1177\/0269881117731279"},{"key":"e_1_3_2_22_1","doi-asserted-by":"crossref","unstructured":"Griffiths RR Johnson MW Richards WA et al. (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology 218(4): 649\u2013665. https:\/\/doi.org\/10.1007\/S00213-011-2358-5","DOI":"10.1007\/s00213-011-2358-5"},{"key":"e_1_3_2_23_1","doi-asserted-by":"crossref","unstructured":"Griffiths RR Richards WA Johnson MW et al. (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology (Oxford England) 22(6): 621\u2013632. https:\/\/doi.org\/10.1177\/0269881108094300","DOI":"10.1177\/0269881108094300"},{"key":"e_1_3_2_24_1","doi-asserted-by":"crossref","unstructured":"Griffiths RR Richards WA McCann U et al. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187(3): 268\u2013283. https:\/\/doi.org\/10.1007\/S00213-006-0457-5\/FIGURES\/4","DOI":"10.1007\/s00213-006-0457-5"},{"key":"e_1_3_2_25_1","doi-asserted-by":"crossref","unstructured":"Gukasyan N Davis AK Barrett FS et al. (2022) Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology (Oxford England) 36(2): 151\u2013158. https:\/\/doi.org\/10.1177\/02698811211073759","DOI":"10.1177\/02698811211073759"},{"key":"e_1_3_2_26_1","doi-asserted-by":"crossref","unstructured":"Haig BD (2023) Repositioning construct validity theory: From nomological networks to pragmatic theories and their evaluation by explanatory means. Perspectives on Psychological Science 20(2): 340. https:\/\/doi.org\/10.1177\/17456916231195852","DOI":"10.1177\/17456916231195852"},{"key":"e_1_3_2_27_1","doi-asserted-by":"crossref","unstructured":"Hanson JA VanderWeele TJ (2021) The comprehensive measure of meaning: Psychological and philosophical foundations. In: Lee MT Kubzansky LD VanderWeele TJ (eds) Measuring Well-Being: Interdisciplinary Perspectives from the Social Sciences and the Humanities. Oxford Academic pp. 339\u2013376. https:\/\/doi.org\/10.1093\/OSO\/9780197512531.003.0013","DOI":"10.1093\/oso\/9780197512531.003.0013"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.2546"},{"key":"e_1_3_2_29_1","doi-asserted-by":"crossref","unstructured":"Johnson MW Garcia-Romeu A Griffiths RR (2017) Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse 43(1): 55\u201360. https:\/\/doi.org\/10.3109\/00952990.2016.1170135","DOI":"10.3109\/00952990.2016.1170135"},{"key":"e_1_3_2_30_1","doi-asserted-by":"crossref","unstructured":"Kangaslampi S (2023) Association between mystical-type experiences under psychedelics and improvements in well-being or mental health \u2013 A comprehensive review of the evidence. Journal of Psychedelic Studies 7(1): 18\u201328. https:\/\/doi.org\/10.1556\/2054.2023.00243","DOI":"10.1556\/2054.2023.00243"},{"key":"e_1_3_2_31_1","doi-asserted-by":"crossref","unstructured":"Leone L McSpadden B DeMarco A et al. (2024) Psychedelics and evidence-based psychotherapy: A systematic review with recommendations for advancing psychedelic therapy research. Psychiatric Clinics of North America 47(2): 367\u2013398. https:\/\/doi.org\/10.1016\/j.psc.2024.02.006","DOI":"10.1016\/j.psc.2024.02.006"},{"key":"e_1_3_2_32_1","doi-asserted-by":"crossref","unstructured":"Maji\u0107 T Schmidt TT Gr\u00f6ticke A et al. (2025) The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics. Journal of Psychopharmacology (Oxford England) 39(5): 474. https:\/\/doi.org\/10.1177\/02698811251326937","DOI":"10.1177\/02698811251326937"},{"key":"e_1_3_2_33_1","doi-asserted-by":"crossref","unstructured":"McCulloch DEW Grzywacz MZ Madsen MK et al. (2022a) Psilocybin-induced mystical-type experiences are related to persisting positive effects: A quantitative and qualitative report. Frontiers in Pharmacology 13: 1\u201317. https:\/\/doi.org\/10.3389\/FPHAR.2022.841648","DOI":"10.3389\/fphar.2022.841648"},{"key":"e_1_3_2_34_1","doi-asserted-by":"crossref","unstructured":"McCulloch DEW Knudsen GM Barrett FS et al. (2022b) Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses. Neuroscience and Biobehavioral Reviews 138: 104689. https:\/\/doi.org\/10.1016\/J.NEUBIOREV.2022.104689","DOI":"10.1016\/j.neubiorev.2022.104689"},{"key":"e_1_3_2_35_1","doi-asserted-by":"crossref","unstructured":"Mithoefer MC Wagner MT Mithoefer AT et al. (2011) The safety and efficacy of {+\/-}3 4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. Journal of Psychopharmacology (Oxford England) 25(4): 439\u2013452. https:\/\/doi.org\/10.1177\/0269881110378371","DOI":"10.1177\/0269881110378371"},{"key":"e_1_3_2_36_1","doi-asserted-by":"crossref","unstructured":"Mueller RO Hancock GR (2015) Factor analysis and latent structure analysis: Confirmatory factor analysis. In: Wright JD (ed.) International Encyclopedia of the Social & Behavioral Sciences: Second Edition. Elsevier pp. 686\u2013690. https:\/\/doi.org\/10.1016\/B978-0-08-097086-8.25009-5","DOI":"10.1016\/B978-0-08-097086-8.25009-5"},{"key":"e_1_3_2_37_1","doi-asserted-by":"crossref","unstructured":"Nayak SM Jackson H Sepeda ND et al. (2023) Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: Results from a prospective longitudinal survey. Frontiers in Psychiatry 14: 1199642. https:\/\/doi.org\/10.3389\/FPSYT.2023.1199642\/BIBTEX","DOI":"10.3389\/fpsyt.2023.1199642"},{"key":"e_1_3_2_38_1","doi-asserted-by":"crossref","unstructured":"Nicholas CR Henriquez KM Gassman MC et al. (2018) High dose psilocybin is associated with positive subjective effects in healthy volunteers. Journal of Psychopharmacology (Oxford England) 32(7): 770\u2013778. https:\/\/doi.org\/10.1177\/0269881118780713","DOI":"10.1177\/0269881118780713"},{"key":"e_1_3_2_39_1","doi-asserted-by":"crossref","unstructured":"Nour MM Evans L Nutt D et al. (2016a) Ego-dissolution and psychedelics: Validation of the Ego-Dissolution Inventory (EDI). Frontiers in Human Neuroscience 10: 269. https:\/\/doi.org\/10.3389\/FNHUM.2016.00269","DOI":"10.3389\/fnhum.2016.00269"},{"key":"e_1_3_2_40_1","doi-asserted-by":"crossref","unstructured":"Nour MM Evans L Nutt D et al. (2016b) Ego-dissolution and psychedelics: Validation of the ego-dissolution inventory (EDI). Frontiers in Human Neuroscience 10: 190474. https:\/\/doi.org\/10.3389\/FNHUM.2016.00269\/BIBTEX","DOI":"10.3389\/fnhum.2016.00269"},{"key":"e_1_3_2_41_1","unstructured":"Pahnke WN (1963) Drugs and Mysticism: An Analysis of the Relationship between Psychedelic Drugs and the Mystical Consciousness. Harvard University. Available at: https:\/\/maps.org\/images\/pdf\/books\/pahnke\/walter_pahnke_drugs_and_mysticism.pdf"},{"key":"e_1_3_2_42_1","doi-asserted-by":"crossref","unstructured":"Perkins D Halman A Urokohara A et al. (2025) Acute experiences and persisting psychological effects associated with an encapsulated DMT-harmala alkaloid combination: results of a phase 1 study. Scientific Reports 15: 41152. https:\/\/doi.org\/10.1038\/s41598-025-25767-x","DOI":"10.1038\/s41598-025-25767-x"},{"key":"e_1_3_2_43_1","doi-asserted-by":"crossref","unstructured":"Raison CL Jain R Penn AD et al. (2022) Effects of naturalistic psychedelic use on depression anxiety and well-being: Associations with patterns of use reported harms and transformative mental states. Frontiers in Psychiatry 13: 831092. https:\/\/doi.org\/10.3389\/FPSYT.2022.831092\/BIBTEX","DOI":"10.3389\/fpsyt.2022.831092"},{"key":"e_1_3_2_44_1","doi-asserted-by":"crossref","unstructured":"Raison CL Sanacora G Woolley J et al. (2023) Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial. JAMA 330(9): 843\u2013853. https:\/\/doi.org\/10.1001\/jama.2023.14530","DOI":"10.1001\/jama.2023.14530"},{"key":"e_1_3_2_45_1","doi-asserted-by":"crossref","unstructured":"Rieser NM Gubser LP Moujaes F et al. (2023) Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences. Scientific Reports 13(1): 17475. https:\/\/doi.org\/10.1038\/S41598-023-44153-Z","DOI":"10.1038\/s41598-023-44153-z"},{"key":"e_1_3_2_46_1","doi-asserted-by":"crossref","unstructured":"Salsman JM Lai JS Hendrie HC et al. (2014). Assessing psychological well-being: self-report instruments for the NIH Toolbox. Quality of Life Research 23(1): 205\u2013215. https:\/\/doi.org\/10.1007\/S11136-013-0452-3","DOI":"10.1007\/s11136-013-0452-3"},{"key":"e_1_3_2_47_1","doi-asserted-by":"crossref","unstructured":"Salsman JM Butt Z Pilkonis PA et al. (2013) Emotion assessment using the NIH Toolbox. Neurology 80(11 Suppl 3): S76. https:\/\/doi.org\/10.1212\/WNL.0B013E3182872E11","DOI":"10.1212\/WNL.0b013e3182872e11"},{"key":"e_1_3_2_48_1","doi-asserted-by":"crossref","unstructured":"Schmid Y Liechti ME (2018) Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology 235(2): 535\u2013545. https:\/\/doi.org\/10.1007\/S00213-017-4733-3","DOI":"10.1007\/s00213-017-4733-3"},{"key":"e_1_3_2_49_1","doi-asserted-by":"crossref","unstructured":"Stocker K Hartmann M Schmid Y et al. (2025) The 3D-ASCr Scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research. Journal of Psychopharmacology (Oxford England) 40(5): 850\u2013862. https:\/\/doi.org\/10.1177\/02698811251397328","DOI":"10.1177\/02698811251397328"},{"key":"e_1_3_2_50_1","doi-asserted-by":"crossref","unstructured":"Studerus E Gamma A Vollenweider FX (2010) Psychometric evaluation of the altered states of Consciousness Rating Scale (OAV). PLoS One 5(8): e12412. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0012412","DOI":"10.1371\/journal.pone.0012412"},{"key":"e_1_3_2_51_1","doi-asserted-by":"crossref","unstructured":"Studerus E Kometer M Hasler F et al. (2011) Acute subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies. Journal of Psychopharmacology 25(11): 1434\u20131452. https:\/\/doi.org\/10.1177\/0269881110382466","DOI":"10.1177\/0269881110382466"},{"key":"e_1_3_2_52_1","doi-asserted-by":"crossref","unstructured":"Sznitman SR Behar YA Dicker-Oren SD et al. (2025) A prospective ecological momentary assessment study of an ayahuasca retreat: Exploring the salutary impact of acute psychedelic experiences on subacute affect and mindfulness skills in daily life. Psychopharmacology 242(3): 545\u2013561. https:\/\/doi.org\/10.1007\/S00213-024-06704-8","DOI":"10.1007\/s00213-024-06704-8"},{"key":"e_1_3_2_53_1","doi-asserted-by":"crossref","unstructured":"Taves A Ihm E Wolf M et al. (2023) The Inventory of Nonordinary Experiences (INOE): Evidence of validity in the United States and India. PLoS One 18(7): e0287780. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0287780","DOI":"10.1371\/journal.pone.0287780"},{"key":"e_1_3_2_54_1","doi-asserted-by":"crossref","unstructured":"Urban EJ Charles ST Levine LJ et al. (2018) Depression history and memory bias for specific daily emotions. PLoS One 13(9): e0203574. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0203574","DOI":"10.1371\/journal.pone.0203574"},{"key":"e_1_3_2_55_1","doi-asserted-by":"crossref","unstructured":"Viktorin V Gri\u0161kova-Bulanova I Voicikas A et al. (2022) Psilocybin-mediated attenuation of gamma band Auditory Steady-State Responses (ASSR) is driven by the intensity of cognitive and emotional domains of psychedelic experience. Journal of Personalized Medicine 12(6): 1004. https:\/\/doi.org\/10.3390\/JPM12061004","DOI":"10.3390\/jpm12061004"},{"key":"e_1_3_2_56_1","doi-asserted-by":"crossref","unstructured":"Watkins MW (2018) Exploratory factor analysis: A guide to best practice. Journal of Black Psychology 44(3): 219\u2013246. https:\/\/doi.org\/10.1177\/0095798418771807","DOI":"10.1177\/0095798418771807"},{"key":"e_1_3_2_57_1","doi-asserted-by":"crossref","unstructured":"Wolf MG Ihm E Maul A et al. (2025) The response-process-evaluation method: A new approach to survey-item validation. Advances in Methods and Practices in Psychological Science. Epub ahead of print 12 August 2025. https:\/\/doi.org\/10.1177\/25152459251353135","DOI":"10.1177\/25152459251353135"},{"key":"e_1_3_2_58_1","doi-asserted-by":"crossref","unstructured":"Yaden DB Haybron DM (2022) The emotional state assessment tool: A brief philosophically informed and cross-culturally sensitive measure. Journal of Positive Psychology 17(2): 151\u2013165. https:\/\/doi.org\/10.1080\/17439760.2021.2016910","DOI":"10.1080\/17439760.2021.2016910"},{"key":"e_1_3_2_59_1","doi-asserted-by":"crossref","unstructured":"Yaden DB Yaden ME Griffiths RR (2021) Psychedelics in psychiatry\u2013Keeping the renaissance from going off the rails. JAMA Psychiatry 78(5): 469\u2013470. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3672","DOI":"10.1001\/jamapsychiatry.2020.3672"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261473405","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261473405","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261473405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T07:20:22Z","timestamp":1789888822000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261473405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":58,"alternative-id":["10.1177\/02698811261473405"],"URL":"https:\/\/doi.org\/10.1177\/02698811261473405","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"02698811261473405"}}